Fig. 1: Identification of autoantibodies using a protein microarray platform and aCOX-2 antibodies in different IAA cohorts.
From: Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia
A Autoantibody screening results from patients with large granular lymphocyte (LGL) leukemia (n = 12), immune aplastic anemia (n = 7) and rheumatoid arthritis (n = 10) were compared to the mean values from healthy controls (HC, n = 5). All values that were more than ten times higher than the mean of fold change of HC were considered as positive. Heat map presents data from all individual antibodies that were positive in at least two individual AA patients. RA Rheumatoid Arthritis. B Dashed line denotes the statistical cutoff value determined from combined cohort data. aCOX-2 Ab results expressed as DELFIA counts from the United States (USA), Japan (JPN) and Nordic (NORD) IAA patient cohorts. C Percentages of aCOX-2 positive in pediatric (<18 years old) and adult (>18 years old) IAA patients. D Percentages of aCOX-2 Ab positive IAA patients in age groups divided into 10-year intervals. E Median ages at diagnosis and interquartile ranges are presented for all IAA patients included in the USA, Japanese (JPN) and Nordic (NORD) patient cohorts. ANOVA was used for comparisons between the groups.
